Lifotronic(SH:688389)2024-04-25 09:46Financial Performance - In Q1 2024, Lifotronic reported revenue of 306 million CNY, representing a year-over-year growth of 10.06%[1] - The net profit attributable to shareholders for Q1 2024 was 107 million CNY, showing a year-over-year increase of 21.69%[1] - Domestic market revenue reached 229 million CNY in Q1 2024, with a significant year-over-year growth of 75.00%[1] - International market revenue was 34.73 million CNY in Q1 2024, reflecting a year-over-year increase of 25.00%[1] - The revenue from domestic in vitro diagnostics was 72 million CNY, with a year-over-year growth of 28%[1] Research and Development - The company's R&D investment in Q1 2024 was 36.6 million CNY, accounting for 14.30% of its revenue[1] - Lifotronic has accumulated 227 authorized patents, including 56 invention patents and 49 software copyright certificates[2] - The company has been recognized as a "Smart Health and Elderly Care Application Pilot Demonstration" enterprise, valid from January 6, 2024, to January 5, 2027[5] - Lifotronic's subsidiary was awarded the title of "Advanced Enterprise in R&D Investment" for 2023 in the Dongguan Songshan Lake area[5] Future Plans - The company plans to hold a Q1 2024 earnings presentation on May 24, 2024, to provide further insights into its operations[6]